In patients with Myelofibrosis (MF) treated with ruxolitinib (RUX), the response is unpredictable at therapy start. We retrospectively evaluated the impact of clinical/laboratory factors on responses in 408 patients treated with RUX according to prescribing obligations in 18 Italian Hematology Centers. At 6 months, 114 out of 327 (34.9%) evaluable patients achieved a spleen response. By multivariable Cox proportional hazard regression model, pre-treatment factors negatively correlating with spleen response were: high/intermediate-2 IPSS risk (p=0.024), large splenomegaly (p=0.017), transfusion dependency (p=0.022), platelet count <200×109/l (p=0.028), and a time-interval between MF diagnosis and RUX start >2 years (p=0.048). Also, patients treated with higher (≥10 mg BID) average RUX doses in the first 12 weeks achieved higher response rates (p=0.019). After adjustment for IPSS risk, patients in spleen response at 6 months showed only a trend for better survival compared to non-responders. At 6 months, symptoms response was achieved by 85.5% of 344 evaluable patients; only a higher (>20) Total Symptom Score significantly correlated with lower probability of response (p<0.001). Increased disease severity, a delay in RUX start and titrated doses <10 mg BID were associated with patients achievinglower response rates. An early treatment and higher RUX doses may achieve better therapeutic results.

Palandri, F., Palumbo, G.A., Bonifacio, M., Tiribelli, M., Benevolo, G., Martino, B., et al. (2017). Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. ONCOTARGET, 8(45), 79073-79086 [10.18632/oncotarget.18674].

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis

Palandri, Francesca;Polverelli, Nicola;Spinsanti, Marco;Sabattini, Elena;Catani, Lucia;Lemoli, Roberto Massimo;Russo, Domenico;Cuneo, Antonio;Bacchi Reggiani, Maria Letizia;Cavo, Michele;Vianelli, Nicola;
2017

Abstract

In patients with Myelofibrosis (MF) treated with ruxolitinib (RUX), the response is unpredictable at therapy start. We retrospectively evaluated the impact of clinical/laboratory factors on responses in 408 patients treated with RUX according to prescribing obligations in 18 Italian Hematology Centers. At 6 months, 114 out of 327 (34.9%) evaluable patients achieved a spleen response. By multivariable Cox proportional hazard regression model, pre-treatment factors negatively correlating with spleen response were: high/intermediate-2 IPSS risk (p=0.024), large splenomegaly (p=0.017), transfusion dependency (p=0.022), platelet count <200×109/l (p=0.028), and a time-interval between MF diagnosis and RUX start >2 years (p=0.048). Also, patients treated with higher (≥10 mg BID) average RUX doses in the first 12 weeks achieved higher response rates (p=0.019). After adjustment for IPSS risk, patients in spleen response at 6 months showed only a trend for better survival compared to non-responders. At 6 months, symptoms response was achieved by 85.5% of 344 evaluable patients; only a higher (>20) Total Symptom Score significantly correlated with lower probability of response (p<0.001). Increased disease severity, a delay in RUX start and titrated doses <10 mg BID were associated with patients achievinglower response rates. An early treatment and higher RUX doses may achieve better therapeutic results.
2017
Palandri, F., Palumbo, G.A., Bonifacio, M., Tiribelli, M., Benevolo, G., Martino, B., et al. (2017). Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. ONCOTARGET, 8(45), 79073-79086 [10.18632/oncotarget.18674].
Palandri, Francesca; Palumbo, Giuseppe Alberto; Bonifacio, Massimiliano; Tiribelli, Mario; Benevolo, Giulia; Martino, Bruno; Abruzzese, Elisabetta; D'...espandi
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/614585
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 72
  • ???jsp.display-item.citation.isi??? 68
social impact